Review Article
S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine
Table 3
Meta-analyses of S-amlodipine in hypertension.
| | Author (year) | Country | S-AM
(mg) | Comparator
(mg) | | Duration
(weeks) | Antihypertensive efficacy | AEs |
| | Liu et al. (2010) [30] | China | 2.5 | Amlo (5) | 15 trials | 4–40 | All trials: Similar efficacy
Only high-quality trials: WMD for decrease in SBP/DBP at
4 weeks: −2.84/−1.71
8 weeks: −1.38/−1.33 | Similar;
RD: all trials: −0.04; High quality: −0.04 |
| | Zhao and Chen (2015) [31] | China | NA | Amlo | 8 trials: 732/724 | NA | Significantly better efficacy of S-AM than Amlo: OR 2.19 | Significantly lower rate of AEs: OR 0.51 |
|
|
AEs: adverse effects, Amlo: racemic amlodipine, BP: blood pressure, DBP: diastolic BP, NA: not available, OR: odds ratio, RD: risk difference, S-AM: S-amlodipine, and SBP: systolic BP.
|
